Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Fiche publication
Date publication
mars 2021
Journal
Cancer medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe
Tous les auteurs :
Passildas-Jahanmohan J, Eymard JC, Pouget M, Kwiatkowski F, Van Praagh I, Savareux L, Atger M, Durando X, Abrial C, Richard D, Ginzac Couvé A, Thivat E, Monange B, Chollet P, Mahammedi H
Lien Pubmed
Résumé
Metastatic castration-resistant prostate cancer (mCRPC) patients have a poor prognosis, and curcumin is known to have antineoplastic properties. On the basis of previous phase I and phase II studies, we investigated whether the association of curcumin with docetaxel could improve prognosis among mCRPC patients.
Mots clés
chemotherapy, curcumin, docetaxel, metastatic castration-resistant prostate cancer, phase II, randomized trial
Référence
Cancer Med. 2021 Mar 5;: